Addex Therapeutics Ltd

ADXN

CH0029850754

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:10 2024-05-10 am EDT			5-day change	1st Jan Change
0.073 ^CHF	-0.54%		+7.04%	+58.70%

May. 08	Addex to Present at BioEURquity Europe 2024	DJ
Apr. 30	European Equities Traded in the US as American Depositary Receipts Decline	MT

Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC

December 20, 2021

On December 21, 2021, Addex Therapeutics Ltd closed the transaction.

Latest news about Addex Therapeutics Ltd

Addex to Present at BioEURquity Europe 2024	May. 08	DJ
European Equities Traded in the US as American Depositary Receipts Decline	Apr. 30	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 29	MT
Sector Update: Health Care	Apr. 29	MT
Top Midday Decliners	Apr. 29	MT
Addex Therapeutics Shares Plunge as Phase 2 Study of ADX71149 Falls Short of Primary Goal	Apr. 29	MT
Tech Rally Subsides as US Equity Futures Waver Pre-Bell	Apr. 29	MT
Top Premarket Decliners	Apr. 29	MT
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure	Apr. 29	DJ
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study	Apr. 29	CI
Top Premarket Decliners	Apr. 24	MT
Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024	Apr. 18
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises	Apr. 18	MT
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update	Apr. 18	DJ
ADRs End Higher; Biophytis Climbs 30%	Apr. 09	DJ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09	MT
Top Premarket Gainers	Apr. 09	MT
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	Apr. 08	DJ
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket	Apr. 03	MT
Top Premarket Gainers	Apr. 03	MT
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders	Apr. 03	CI
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders	Apr. 03	DJ
ADRs Close Lower, Lixiang Education Holding Co. Ltd. Declines 19.6%	Mar. 08	DJ
Addex Therapeutics Plans Sale of American Depositary Shares	Jan. 31	MT

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Companyâs clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsonâs disease and mGlu3 PAM for neurodegenerative disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Bio Equity Europe Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.073 CHF

Average target price

0.16 CHF

Spread / Average Target

+119.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADDEX THERAPEUTICS LTD	+58.70%	10.33M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research